Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy
Phase II pilot study of a preoperative induction chemotherapy in combination with Bevacizumab followed by combined radiochemotherapy for patients with locally advanced rectal carcinoma
Rectal Cancer
DRUG: preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine
termination of therapy, before surgery (after conclusion of therapy phase), up to 17 weeks|occurence of toxicity, until timepoint of discharge of patient, up to 18-19 weeks
collection of response rate, T- and N-downstaging, pathological complete remission: measurement at the timepoint of surgery, up to week 18|post-surgery morbidity, according to Accordion; measurement at the timepoint of discharge of patient, after 18-19 weeks
Induction chemotherapy combined with Radio chemotherapy:

Therapy start: within 28 days after bioptical diagnosis capecitabine 1000 mg/m2 bid during 14 days (d1-d14) , oxaliplatin 130 mg/m2 and bevacizumab 7.5 mg/kg body weight d1; repetition day 22 and 43 (3 cycles)

Combined Radiochemotherapy after 1 week of concluded 3rd cycle of induction chemotherapy:

Radiotherapy: 5 x 5 days 1.8 Gy; cumulative dose 45 Gy Chemotherapy: capecitabine 825mg/mÂ² bid, on each radiation day during the first 4 weeks of RCTx

Surgery according to TME-criteria (total mesorectal excision) in compliance of an interruption of min. 14 days after RCTx